SpringerLink
Log in

Pegvisomant in acromegaly: Why, when, how

  • Opinion Document
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102–52.

    Article  PubMed  CAS  Google Scholar 

  2. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355: 2558–73.

    Article  PubMed  CAS  Google Scholar 

  3. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90: 4465–73.

    Article  PubMed  CAS  Google Scholar 

  4. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 4405–10.

    Article  PubMed  CAS  Google Scholar 

  5. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002, 23: 623–46.

    Article  PubMed  CAS  Google Scholar 

  6. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342: 1171–7.

    Article  PubMed  CAS  Google Scholar 

  7. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358: 1754–9.

    Article  PubMed  Google Scholar 

  8. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006, 154: 467–77.

    Article  PubMed  CAS  Google Scholar 

  9. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007, 156: 75–82.

    Article  PubMed  CAS  Google Scholar 

  10. Jehle S, Reyes CM, Sundeen RE, Freda PU. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 2005, 90: 1588–93.

    Article  PubMed  CAS  Google Scholar 

  11. Ronchi CL, Varca V, Beck-Peccoz P, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006, 91: 121–8.

    Article  PubMed  CAS  Google Scholar 

  12. Lindberg-Larsen R, Moller N, Schmitz O, et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 2007, 92: 1724–8.

    Article  PubMed  CAS  Google Scholar 

  13. Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003, 149: 521–7.

    Article  PubMed  CAS  Google Scholar 

  14. Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002, 87: 1692–9.

    Article  PubMed  CAS  Google Scholar 

  15. Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 2007, 92: 476–82.

    Article  PubMed  CAS  Google Scholar 

  16. Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005, 20: 1837–44.

    Article  PubMed  Google Scholar 

  17. Fairfield WP, Sesmilo G, Katznelson L, et al. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol (Oxf) 2002, 57: 385–90.

    Article  CAS  Google Scholar 

  18. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 2003, 88: 5650–5.

    Article  PubMed  CAS  Google Scholar 

  19. Biering H, Saller B, Bauditz J, et al. German pegvisomant investigators. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 2006, 154: 213–20.

    Article  PubMed  CAS  Google Scholar 

  20. Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 2005, 153: 187–93.

    Article  PubMed  CAS  Google Scholar 

  21. Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 2006, 145: 310–2.

    Article  PubMed  Google Scholar 

  22. Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 2007, 92: 3374–7.

    Article  PubMed  CAS  Google Scholar 

  23. Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 1856–63.

    Article  PubMed  CAS  Google Scholar 

  24. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 2006, 29: 86–93.

    Article  PubMed  CAS  Google Scholar 

  25. van der Lely AJ, Muller AF, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist Pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001, 86: 478–81.

    Article  PubMed  Google Scholar 

  26. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87: 3013–8.

    Article  PubMed  CAS  Google Scholar 

  27. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005, 90: 5627–31.

    Article  PubMed  CAS  Google Scholar 

  28. Aimaretti G, Boschetti M, Corneli G et al. Normal age-dependent values of serum insulin growth factor (IGF)-I: italian healthy population. J Endocrinol Invest 2007, in press.

  29. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein−1, −2, and −3. J Clin Endocrinol Metab 2001, 86: 1091–8.

    PubMed  CAS  Google Scholar 

  30. Drake WM, Loureiro RA, Parkinson C, Monson JP, Besser GM, Trainer PJ. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant. Eur J Endocrinol 2005, 152: 47–51

    Article  PubMed  CAS  Google Scholar 

  31. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005, 365: 1644–6.

    Article  PubMed  CAS  Google Scholar 

  32. Galland F, Kamenicky P, Affres H, et al. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J Clin Endocrinol Metab 2006, 91: 4957–61.

    Article  PubMed  CAS  Google Scholar 

  33. Harris P, D’Souza G, Good A et al. A comparison between the efficacy and safety of pegvisomant to that of octreotide LAR in patients with acromegaly. Program of the 9th European Congress of Endocrinology, Budapest, Hungary, 2007, P610 (abstract).

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples

    A. Colao, G. Lombardi & R. Pivonello

  2. Department of Internal Medicine, University of Ancona, Ancona

    G. Arnaldi

  3. Institute of Endocrine Sciences, University of Milan, Milan

    P. Beck-Peccoz

  4. Endocrine Section, Department of Medicine and Pharmacology, University of Messina, Messina

    S. Cannavò

  5. Division of Endocrinology, Niguarda Hospital, Milan

    R. Cozzi

  6. Endocrine Section, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Ferrara

    E. degli Uberti

  7. Division of Endocrinology, Catholic University, Rome

    L. De Marinis

  8. Service of Endocrinology, Treviso Hospital, Treviso

    E. De Menis

  9. Department of Endocrine and Medical Sciences and Center of Excellence for Biomedical Research, University of Genova, Genova

    D. Ferone & F. Minuto

  10. Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin

    V. Gasco, S. Grottoli & E. Ghigo MD

  11. Endocrine Section, Department of Internal Medicine, University of Brescia, Brescia

    A. Giustina

  12. Clinica Medica III, Department of Medical and Surgical Sciences, University of Padua, Padua

    P. Maffei

  13. Department of Endocrinology and Metabolism, Univerity of Pisa, Pisa, Italy

    E. Martino

Authors
  1. A. Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Arnaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Beck-Peccoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Cannavò
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Cozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. degli Uberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. De Marinis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. De Menis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Ferone
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V. Gasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Giustina
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S. Grottoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P. Maffei
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. E. Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. F. Minuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. R. Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. E. Ghigo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Ghigo MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colao, A., Arnaldi, G., Beck-Peccoz, P. et al. Pegvisomant in acromegaly: Why, when, how. J Endocrinol Invest 30, 693–699 (2007). https://doi.org/10.1007/BF03347452

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347452

Key-words

Search

Navigation